Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 5/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14026612 | 0.89 | PTGDR2 (0.68) | PTGDR2ALDH1A1KDM4ENPC1 | |
| SCHEMBL4607574 | 0.86 | PTGDR2 (0.62) | PTGDR2ALDH1A1KDM4ENPC1 | |
| SCHEMBL4608527 | 0.86 | PTGDR2 (0.75) | PTGDR2 | |
| SCHEMBL4942617 | 0.78 | PTGDR2 (0.63) | PTGDR2 | |
| SCHEMBL4940295 | 0.78 | PTGDR2 (0.63) | PTGDR2ALDH1A1KDM4E | |
| SCHEMBL1713829 | 0.77 | PTGDR2 (1.00) | PTGDR2KMT2A | |
| SCHEMBL4934378 | 0.76 | PTGDR2 (0.83) | PTGDR2 | |
| SCHEMBL4939937 | 0.76 | PTGDR2 (0.67) | PTGDR2 | |
| SCHEMBL4622645 | 0.76 | PTGDR2 (0.83) | PTGDR2 | |
| SCHEMBL4942884 | 0.75 | PTGDR2 (0.60) | PTGDR2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255150-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2008-10-16 | — | — | US | disclosed |
| EP-1948630-A2 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2008-07-30 | — | — | EP | disclosed |
| WO-2007052023-A2 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2007-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255150-A1 | Novel Compounds | CFTR, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP11B2 | PTGDR2 620/4885ALDH1A1 239/4885KDM4E 3205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.